pantoprazole has been researched along with lansoprazole in 210 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 41 (19.52) | 18.2507 |
| 2000's | 101 (48.10) | 29.6817 |
| 2010's | 54 (25.71) | 24.3611 |
| 2020's | 14 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Figala, V; Klemm, K; Kohl, B; Krüger, U; Rainer, G; Schaefer, H; Senn-Bilfinger, J; Simon, WA; Sturm, E | 1 |
| Nakamura, K; Nishikawa, Y; Seto, Y; Tada, K; Tanitame, A; Terauchi, H | 1 |
| Fromm, MF; Klotz, U; Pauli-Magnus, C; Rekersbrink, S | 1 |
| Bariwal, J; Bhosale, AV; Jagtap, JR; Jain, KS; Kale, AP; Shah, AK; Shelke, SM | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Castillo, R; Hernández-Campos, A; Hernández-Luis, F; Pérez-Villanueva, J; Romo-Mancillas, A; Yépez-Mulia, L | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Bakmiwewa, SM; Ball, HJ; Fatokun, AA; Hunt, NH; Payne, RJ; Tran, A | 1 |
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Fako, VE; Liu, JY; Pflug, B; Wu, X; Zhang, JT | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bala, V; Chhonker, YS | 1 |
| Beghyn, T; Bosc, D; Charton, J; Deprez, B; Deprez-Poulain, R; Guillaume, V; Herledan, A; Hermant, P; Landry, V; Leroux, F; Liang, W; Pottiez, V; Sheng, L; Tang, WJ; Urata, S; Warenghem, S | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Büdingen, C; Fahr, S; Kinder, B; Koske, M; Simon, WA | 1 |
| Dítĕ, P; Prásek, J | 1 |
| Creutzfeldt, W | 2 |
| Tucker, GT | 1 |
| Arnold, R | 1 |
| Kromer, W | 2 |
| Kaplan, B; Mears, JM | 1 |
| Huber, R; Kolassa, N; Radtke, HW; Steinijans, VW; Zech, K | 1 |
| Andersson, T | 1 |
| Meyer, UA | 1 |
| Leonhardt, U; Ramadori, G; Ritzel, U | 1 |
| Hildebrandt, AG; Kleeberg, U; Krusekopf, S; Ruckpaul, K | 1 |
| Eberle, D; Hummel, RP; Kuhn, R | 1 |
| Florent, C; Forestier, S | 1 |
| Andersson, T; Unge, P | 1 |
| Berstad, A; Hatlebakk, JG | 1 |
| Hakusui, H; Masubuchi, N; Okazaki, O | 2 |
| Bateman, DN | 1 |
| Besancon, M; Sachs, G; Shin, JM; Simon, A | 1 |
| Masubuchi, N; Okazaki, O | 1 |
| Andersson, K; Bayati, A; Lee, H; Lorentzon, P | 1 |
| Chiocca, JC; Salis, GB | 1 |
| Malfertheiner, P; Nakao, M | 1 |
| Andersson, T; Holmberg, J; Röhss, K; Walan, A | 1 |
| Hetzel, D | 1 |
| Lambert, JR; Treiber, G | 1 |
| Diehl, KL; Geyer, P; Jaspersen, D; Martens, E; Schoeppner, H | 1 |
| Li, AP; Masubuchi, N; Okazaki, O | 1 |
| Gleiter, CH | 1 |
| Zaigler, M | 1 |
| Dattilo, M; Figura, N | 1 |
| Kato, S; Konaka, A; Nishijima, M; Takeuchi, K; Yasuhiro, T | 1 |
| Addolorato, G; Armuzzi, A; Cammarota, G; Cannizzaro, O; Cianci, R; Gasbarrini, A; Gasbarrini, GB; Papa, A | 1 |
| Faure, C; Languepin, J; Pelatan, C | 1 |
| Horbach, S; Kromer, W; Lühmann, R | 1 |
| Dilger, K; Klotz, U; Zheng, Z | 1 |
| Ekpe, A; Jacobsen, T | 1 |
| Bustamante, M; Stollman, N | 1 |
| Bong, JL; Douglas, WS; Lucke, TW | 1 |
| Moustafa, AA | 1 |
| Goldwater, DR; Hunt, RH; Pan, WJ; Pilmer, BL; Zhang, Y | 1 |
| Malki, SA; Yeomans, ND | 1 |
| Howden, CW | 1 |
| Dunn, NR; Freemantle, S; Martin, RM; Shakir, S | 1 |
| Botta, F; Chiarbonello, B; Fasoli, A; Giannini, E; Lantieri, PB; Malfatti, F; Risso, D; Romagnoli, P; Savarino, V; Testa, R | 1 |
| Thomson, AB | 1 |
| Anic, T; Aralica, G; Bilic, I; Buljat, G; Ivankovic, D; Mikus, D; Mise, S; Perovic, D; Petek, M; Prkacin, I; Rotkvic, I; Rucman, R; Seiwerth, S; Separovic, J; Sikiric, P; Stancic-Rokotov, D; Zoricic, I | 1 |
| Athmann, C; Boldt, JH; Brunner, G | 1 |
| Bradley, CP; Greenfield, SM; Jones, MI; Jowett, S; Seal, R | 1 |
| Bardou, M | 1 |
| Dupas, JL; Houcke, P; Samoyeau, R | 1 |
| Gerson, LB; Triadafilopoulos, G | 1 |
| Tytgat, GN | 1 |
| Chiu, YL; Freston, J; Lukasik, N; Pan, WJ; Täubel, J | 1 |
| Caro, JJ; Salas, M; Ward, A | 1 |
| Herszényi, L; Tulassay, Z | 1 |
| Chiu, YL; Lukasik, NL; Pan, WJ; Pilmer, BL; Sharma, VK; Täubel, JJ | 1 |
| Barth, J; Hahne, W | 1 |
| Appelman, SA; Chiu, YL; Goldwater, DR; Huang, JQ; Hunt, RH; James, CF; Keith, RG; Pilmer, BL; Sridhar, S; Thomson, AB | 1 |
| Anderloni, A; Bianchi Porro, G; Imbesi, V; Maconi, G; Parente, F; Sainaghi, M; Sangaletti, O | 1 |
| Bruni, AT; Ferreira, MM; Leite, VB | 1 |
| Calvet, X; Gisbert, JP; Vallve, M; Vergara, M | 1 |
| Mignon, M; Ramdani, A; Samoyeau, R | 1 |
| de Groot, GH; Mulder, CJ; Otten, MH; Oudkerk Pool, M; Smit, JM; Tan, TG; van Milligen de Wit, AW; Westerveld, BD | 1 |
| Tahboub, RM; Vanderhoff, BT | 1 |
| Morozov, IA | 1 |
| Abdel-Razak, O; Gazy, AA; Mahgoub, H; Moneeb, MS; Wahbi, AA | 1 |
| Frissora, C; Katz, PO | 1 |
| De Micheli, E; Frazzoni, M; Grisendi, A; Savarino, V | 1 |
| Beckerling, A; Gatz, G; Ulmer, HJ | 1 |
| Kleeberg, U; Krusekopf, S; Roots, I | 1 |
| Koelz, HR; Labenz, J; Petersen, KU; Rösch, W | 2 |
| Blum, AL; Dorta, G; Jornod, P; Pantoflickova, D; Ravic, M | 1 |
| Hellström, PM; Vitols, S | 1 |
| Balashova, NN; Busarova, GA; Maev, IV | 1 |
| Chen, Y; Katz, PO; Miner, P; Sostek, M | 1 |
| Castell, DO; Katz, PO; Tutuian, R; Xue, S | 1 |
| Becker, TL; de Mendonça, S; Gambero, A; Maróstica, M; Pedrazzoli, J; Ribeiro, ML | 1 |
| Aeed, H; Avni, Y; Boaz, M; Levine, A; Moss, SF; Niv, Y; Shabat-Sehayek, V; Shevah, O; Shirin, H | 1 |
| Karaoglu, AO; Yasa, MH; Yukselen, V | 1 |
| Ahlström, M; Andersson, TB; Li, XQ; Weidolf, L | 1 |
| Barrientos-Astigarraga, RE; de Nucci, G; Mendes, GD; Oliveira, CH; Peres, O; Rezende, VM | 1 |
| Lind, T; Röhss, K; Wilder-Smith, C | 1 |
| Alonso, C; Bernal, JL; del Nozal, MJ; Jiménez, JJ; Toribio, L | 1 |
| Hill, RK; Larson, N; Simpson, CB; Velazquez, R | 1 |
| D'Ambrosio, LP; Franceschi, M; Leandro, G; Longoa, MG; Orsitto, G; Perri, FC; Pilotto, A; Scarcelli, C | 1 |
| Hellström, PM | 1 |
| Iinuma, K; Kato, S; Konno, M; Maisawa, S; Nakayama, Y; Shimizu, T; Tajiri, H; Toyoda, S; Yoshimura, N | 1 |
| Katz, PO | 2 |
| Arnon, J; Clementi, M; De Santis, M; Diav-Citrin, O; Malm, H; Ornoy, A; Robert-Gnansia, E; Schaefer, C; Shechtman, S; Valti, E; van Tonningen, MR | 1 |
| Babic, Z; Lucijanic-Mlinac, M; Marusic, M; Nesanovic, M; Stajcar, V | 1 |
| Barry, M; Bennett, K; McGowan, B; Tilson, L | 1 |
| Brown, RE; Remák, E; Robinson, A; Yuen, C | 1 |
| Ateş, Y; Bağci, S; Ciğerim, M; Dağalp, K; Kadayifçi, A; Karslioğlu, Y; Savaş, MC; Uygun, A; Yeşilova, Z | 1 |
| Calvet, X; Gomollón, F | 1 |
| Hartmann, HJ; Simon, WA; Sturm, E; Weser, U | 1 |
| Baker, DE | 1 |
| Amer, F; Hunt, B; Kukulka, MJ; Metz, DC; Samra, N; Vakily, M | 1 |
| Avorn, J; Canning, C; Dormuth, CR; Glynn, RJ; Maclure, M; Schneeweiss, S | 1 |
| Goldstein, JL; Liu, S; Miner, PB; Schlesinger, PK; Silberg, DG | 1 |
| Gunaratnam, NT; Inadomi, J; Jessup, TP; Lascewski, DP | 1 |
| El-Bardicy, MG; El-Sherif, ZA; El-Tarras, MF; Mohamed, AO | 1 |
| Clark, DW; Strandell, J | 1 |
| Bozkurt, B; Demirkan, K; Kalyoncu, AF; Karakaya, G | 1 |
| Akyol, H; Barisik, NO; Bingul, S; Colak, E; Kaptanoglu, L; Kucuk, HF; Kurt, N; Torlak, OA | 1 |
| El-Eswed, B; Qaisi, AM; Tutunji, LF; Tutunji, MF | 1 |
| Edwards, SJ; Lind, T; Lundell, L | 1 |
| Brørs, O | 1 |
| Esplugues, JV; Martí-Cabrera, M; Ponce, J | 1 |
| Andersson, S; Nelander, H; Ohlén, K | 1 |
| Forrester, MB | 1 |
| Molnar, B; Mullner, K; Tulassay, Z | 1 |
| Boyer, K; Tolia, V | 1 |
| Andriulli, A; Annese, V; D'Ambrosio, LP; Di Mario, F; Franceschi, M; Leandro, G; Paris, F; Pilotto, A; Scarcelli, C; Seripa, D | 1 |
| Bygum, A; Dam, C | 1 |
| Franck, PF; Geus, WP; Hunfeld, NG; Kuipers, EJ; Mathot, RA; Mulder, PG; Touw, DJ; van Schaik, RH | 1 |
| Pérez-Manauta, J | 1 |
| Alonso, C; Bernal, YL; del Nozal, MJ; Jiménez, JJ; Toribio, L | 1 |
| Andersson, T; Weidolf, L | 1 |
| Brugnera, R; Calabrese, C; Di Febo, G; Gabusi, V; Gionchetti, P; Liguori, G; Rizzello, F; Straforini, G | 1 |
| Charlemagne, A; Fagnani, F; Le Jeunne, P; Mouly, S | 1 |
| Naseri, E; Yenişehirli, A | 1 |
| Bagin, RG; Ballard, ED; Gautille, TC; Howden, CW; Koch, FK | 1 |
| Cho, YK; Choi, WH; Hong, CH; Hong, EJ; Jeon, WK; Kim, BI; Kim, HJ; Oh, SJ; Park, DI; Park, JH; Shon, CI; Song, MJ | 1 |
| Zheng, RN | 1 |
| Pellicano, R | 1 |
| Bharathi, DV; Chatki, PK; Hotha, KK; Jagadeesh, B; Mullangi, R; Naidu, A; Thriveni, K | 1 |
| Furuta, T; Hishida, A; Ikuma, M; Kodaira, C; Nishino, M; Sugimoto, M; Umemura, K; Watanabe, H; Yamade, M | 1 |
| Bretagne, JF | 1 |
| Hunt, RH; Padol, S; Yaghoobi, M; Yuan, Y | 1 |
| Barker, PN; Goldstein, JL; Illueca, M; Katz, PO; Morgan, D; Pandolfino, J | 1 |
| Keyhanfar, F; Mahmoudian, M; Motevalian, M; Noubarani, M | 1 |
| Hunt, R; Sachs, G; Shin, JM | 1 |
| Barreiro, JC; Cass, QB; Vanzolini, KL | 1 |
| Benninga, MA; Omari, TI; Smits, MJ; Tabbers, MM; van der Pol, RJ; van Wijk, MP | 1 |
| Buckley, DB; Kazmi, F; Ogilvie, BW; Paris, BL; Parkinson, A; Rostami-Hodjegan, A; Toren, P; Yerino, P | 1 |
| Buyukafsar, K; Erenmemisoglu, A; Ozkur, M; Pektas, M; Un, I; Yurtsever, AS | 1 |
| Eberlein, B; Gebhardt, E; Gilbertz, KP; Placzek, M; Przybilla, B | 1 |
| Gao, J; Gao, S; Gong, YF; Guo, XR; Li, Z; Li, ZS; Liao, Z; Liu, P; Zhan, XB | 1 |
| Bernasconi, GC; Cass, QB; Cassiano, NM; Oliveira, RV | 1 |
| Chang, SY; Chen, C; Chimalakonda, A; Hurley, J; Rodrigues, AD; Thorndike, D; Vuppugalla, R; Wagner, A; Yang, Z; Zvyaga, T | 1 |
| Chularojanamontri, L; Dhana, N; Jiamton, S; Jongjarearnprasert, K; Kulthanan, K; Manapajon, A; Suvanasuthi, S | 1 |
| Banahan, BF; Bentley, JP; Datar, MV; Mahabaleshwarkar, RK; Null, KD; Strum, MW; Yang, Y | 1 |
| Baker, RD; Baker, SS; Burlingame, AL; Egilmez, NK; Forte, JG; Liu, W; Trinidad, J; Virtuoso, LP; Zhu, L | 1 |
| Bhushan, R; Dixit, S; Dubey, R | 1 |
| Hatlebakk, JG; Jonasson, C; Tvete, IF | 1 |
| Forte, JG; Guan, S; Machen, TE; Watson, C; Zhu, L | 1 |
| Afonso, C; Rajab, A; Rudler, H; Seuleiman, M; Touma, M | 1 |
| Angioli, R; Damiani, P; Improta, G; Petrella, C; Plotti, F; Scarpignato, C; Severini, C; Signore, F; Terranova, C | 1 |
| Cao, Z; Kang, T; Tian, C; Yu, D; Zhu, L; Zhu, R | 1 |
| Kim, EH; Kim, HY; Lee, SK; Park, CH; Roh, YH | 1 |
| Bilker, WB; Brensinger, CM; Flockhart, DA; Freeman, CP; Hennessy, S; Kasner, SE; Kimmel, SE; Leonard, CE | 1 |
| Hauser, G; JajacKnez, A; Salkic, N; Stimac, D; Vukelic, K | 1 |
| Akers, KS; Boyd, NK; Niece, KL | 1 |
| Benjak, A; Busso, P; Cole, ST; Pojer, F; Rybniker, J; Sala, C; Vocat, A | 1 |
| Saniee, P; Shahreza, S; Siavoshi, F | 1 |
| Accassat, S; Basset, T; Bertoletti, L; Delavenne, X; Hodin, S; Mismetti, P; Ollier, E | 1 |
| Abbas, MG; Akter, N; Akter, S; Bhuiyan, MA; Hassan, MR; Shahriar, M | 1 |
| Andabak, M; Babic, Z; Banic, M; Bilić, B; Bogdanovic, Z; Dorosulic, Z; Heinzl, R; Kujundzic, M; Marusic, M; Petrovic, Z | 1 |
| Jang, BI; Jung, YS; Kim, KO; Kim, TN; Lee, SH | 1 |
| Christensen, RD; Haastrup, PF; Hansen, JM; Jarbøl, DE; Paulsen, MS; Søndergaard, J | 1 |
| Chen, MH; Chu, CJ; Hou, MC; Huang, YH; Lee, FY; Lin, HC; Lu, CL; Su, TP; Tsai, CF; Wang, YP | 1 |
| Aydın, D; Çelebi, A; Hülagü, S; Kocaman, O; Konduk, BT; Şentürk, Ö | 1 |
| Li, MJ; Li, Q; Liu, LQ; Sun, M | 1 |
| Bhaskaran, K; Douglas, IJ; Langan, S; Smeeth, L; Thomas, S; Tomlinson, LA; Yates, TA | 1 |
| Argyropoulos, T; Briki, A; Chatzidakis, G; Kpogho, I; Malliou, P; Poulou, A; Ravanis, G; Sgourakis, G; Stankovičová, T; Tsuruhara, H; Vagia, A | 1 |
| Chen, D; Fei, G; Lu, B; Wang, B; Wang, J; Wang, X; Wu, B; Zhang, L; Zou, D; Zou, X | 1 |
| Calissendorff, J; Falhammar, H; Lindh, JD; Mannheimer, B; Nathanson, D; Skov, J | 1 |
| Kan, LD; Li, LC; Wu, CY; Ying, J; Yu, ZW | 1 |
| Jiao, HW; Li, YQ; Liu, Y; Shen, YW; Sun, LN; Wang, MF; Wang, YQ; Xie, LJ; Xu, YH; Yu, L; Zhang, HW; Zhang, XH | 1 |
| Karimova, MM; Makarenko, OV; Masheiko, AM; Onul, NM | 1 |
| Foroumadi, A; Kadkhodaei, S; Kolahdoozan, S; Sarrafnejad, A; Siavoshi, F | 1 |
| Abu-Rish, EY; Dahabiyeh, LA; Taha, MO | 1 |
| Ding, H; Hu, L; Huang, Q; Jiang, Y; Liu, Q; Liu, S; Yin, T | 1 |
| Abed, MN; Alassaf, FA; Alfahad, M; Jasim, MHM; Qazzaz, ME | 1 |
| Huang, X; Liu, Y; Shen, Y; Su, YW; Sun, LN; Wang, YQ; Yang, YQ; Ying, YW; Zhang, XH; Zhang, Y | 1 |
| Arnaud, B; Arnoult, C; Escoffier, J; Hograindleur, JP; Kaba, M; Le Blévec, E; Martinez, G; Nef, S; Ray, PF; Stévant, I | 1 |
| Abramenko, N; Antonyová, V; Brogyányi, T; Dytrych, P; Ikeda-Saito, M; Jakubek, M; Kaplánek, R; Kejík, Z; Martásek, P; Pajková, M; Sýkora, D; Tatar, A; Veselá, K | 1 |
| Chen, F; Fang, B; He, X; Wang, S | 1 |
| Latifah, N; Ramadhani, M | 1 |
| Chan, AT; Choi, HK; Lei, G; Lu, N; Misra, D; Neogi, T; Wei, J; Zeng, C; Zhang, Y | 1 |
| Chen, Y; Hou, Y; Li, H; Li, S; Lin, J; Liu, T; Ma, Y; Wang, Y; Yang, H; Zhang, X; Zhang, Y; Zhou, L; Zhou, X | 1 |
| Lespessailles, E; Toumi, H | 1 |
| Chen, X; Jiang, H; Lu, S; Ma, Z; Xu, S; Yang, X; Zhang, Y; Zhao, J; Zhou, H | 1 |
53 review(s) available for pantoprazole and lansoprazole
| Article | Year |
|---|---|
Recent advances in proton pump inhibitors and management of acid-peptic disorders.
Topics: Animals; Anti-Ulcer Agents; Gastric Acid; Gastroesophageal Reflux; Helicobacter Infections; Humans; Peptic Ulcer; Proton Pump Inhibitors | 2007 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Recent developments in anti-Trichomonas research: An update review.
Topics: Antiparasitic Agents; Biological Products; Dose-Response Relationship, Drug; Humans; Molecular Structure; Parasitic Sensitivity Tests; Structure-Activity Relationship; Trichomonas; Trichomonas Infections | 2018 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
[Proton pump blockers and their significance in gastroenterology].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Peptic; Gastrointestinal Diseases; Humans; Lansoprazole; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Sulfoxides; Zollinger-Ellison Syndrome | 1995 |
[Are proton pump inhibitors safe?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Benzimidazoles; Carcinogenicity Tests; Gastric Acid; Humans; Lansoprazole; Mutagenicity Tests; Omeprazole; Pantoprazole; Parietal Cells, Gastric; Peptic Ulcer; Prodrugs; Proton Pump Inhibitors; Structure-Activity Relationship; Sulfoxides | 1994 |
The interaction of proton pump inhibitors with cytochromes P450.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Benzimidazoles; Cytochrome P-450 Enzyme System; Half-Life; Humans; Lansoprazole; Microsomes, Liver; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides | 1994 |
Safety of proton pump inhibitors--an overview.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Benzimidazoles; Cytochrome P-450 Enzyme System; Disease Models, Animal; Drug Interactions; Enterochromaffin Cells; Gastrins; Humans; Lansoprazole; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Sulfoxides | 1994 |
Similarities and differences in the properties of substituted benzimidazoles: a comparison between pantoprazole and related compounds.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cytochrome P-450 Enzyme Inhibitors; Gastric Acid; Humans; Lansoprazole; Omeprazole; Pantoprazole; Sulfoxides | 1995 |
Proton pump inhibitors: new drugs and indications.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Enzyme Inhibitors; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Proton Pumps; Sulfoxides | 1996 |
Pharmacokinetics and drug interactions--relevant factors for the choice of a drug.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Benzimidazoles; Drug Interactions; Enzyme Inhibitors; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides | 1996 |
Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Lansoprazole; Liver; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides | 1996 |
Drug interactions with proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Pantoprazole; Sulfoxides | 1997 |
Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Benzimidazoles; Cimetidine; Cisapride; Domperidone; Famotidine; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Lansoprazole; Metoclopramide; Nizatidine; Omeprazole; Pantoprazole; Piperidines; Proton Pump Inhibitors; Ranitidine; Sucralfate; Sulfoxides | 1996 |
[Gastroesophageal reflux disease refractory to medical treatment. Which approach: the pill or the scalpel?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Fundoplication; Gastroesophageal Reflux; Humans; Lansoprazole; Laparoscopy; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Recurrence; Sulfoxides | 1997 |
Acid pump inhibitors. The treatment of gastroesophageal reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cisapride; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Lansoprazole; Omeprazole; Pantoprazole; Piperidines; Ranitidine; Sulfoxides | 1998 |
The impact of Helicobacter pylori eradication on peptic ulcer healing.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Gastric Acid; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Odds Ratio; Omeprazole; Pantoprazole; Peptic Ulcer; Ranitidine; Stomach Ulcer; Sulfoxides; Treatment Outcome; Wound Healing | 1998 |
Helicobacter pylori infection, chronic gastritis, and proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Chronic Disease; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides | 1998 |
[Proton pump inhibitors in pediatrics].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Child; Enzyme Inhibitors; Humans; Lansoprazole; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Proton-Translocating ATPases; Sulfoxides | 1999 |
Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationship, Drug; Duodenal Ulcer; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Stomach Ulcer; Sulfoxides | 1999 |
The efficacy of proton-pump inhibitors in acute ulcer bleeding: a qualitative review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Humans; Lansoprazole; Omeprazole; Pantoprazole; Peptic Ulcer Hemorrhage; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Recurrence; Stomach Ulcer; Sulfoxides; Treatment Outcome | 2000 |
Is it time to adopt proton pump inhibitors in the prevention of non-steroidal anti-inflammatory drug gastropathy?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Benzimidazoles; Enzyme Inhibitors; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Stomach Diseases; Sulfoxides | 2000 |
Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Interactions; Duodenal Ulcer; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2000 |
[H2 receptor antagonists and proton pump inhibitors: principles and rules of use].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Aged; Anti-Ulcer Agents; Benzimidazoles; Child; Child, Preschool; Duodenal Ulcer; Enzyme Inhibitors; Esophagitis, Peptic; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Infant; Infant, Newborn; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Ranitidine; Stomach Ulcer; Sulfoxides | 2001 |
Proton pump inhibitors and their drug interactions: an evidence-based approach.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Enzyme Inhibitors; Gastrointestinal Agents; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2001 |
Shortcomings of the first-generation proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Biological Availability; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Gastric Acid; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides | 2001 |
Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Rabeprazole; Randomized Controlled Trials as Topic; Ranitidine; Sulfoxides; Treatment Outcome | 2001 |
[Comparative study of proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Duodenal Ulcer; Enzyme Inhibitors; Gastric Acid; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Proton-Translocating ATPases; Rabeprazole; Stomach Ulcer; Sulfoxides | 2001 |
Review article: rabeprazole-based therapy in Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2002 |
Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Pantoprazole; Penicillins; Proton Pump Inhibitors; Rabeprazole; Sulfoxides; Treatment Outcome | 2002 |
The pharmacology and clinical relevance of proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Gastric Acid; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides; Treatment Outcome | 2002 |
Recent use of proton pump inhibitor-based triple therapies for the eradication of H pylori: a broad data review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides | 2003 |
[All proton pump inhibitors are equally efficacious in standard dosages].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationship, Drug; Enzyme Inhibitors; Esomeprazole; Gastric Acid; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2003 |
[Use of proton pump inhibitors in the treatment of gastroesophageal reflux disease].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Enzyme Inhibitors; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides; Treatment Outcome | 2003 |
Effectiveness of proton pump inhibitors: beyond cost.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Enzyme Inhibitors; Esophagitis; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides; Treatment Outcome | 2004 |
What is potent acid inhibition, and how can it be achieved?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic; Esomeprazole; Gastric Acid; Humans; Lansoprazole; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2005 |
Gastroesophageal reflux disease and extraesophageal disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Asthma; Benzimidazoles; Esophageal pH Monitoring; Gastric Acidity Determination; Gastroesophageal Reflux; Heart Diseases; Humans; Lansoprazole; Lung Diseases; Omeprazole; Otorhinolaryngologic Diseases; Pantoprazole; Proton Pump Inhibitors; Sulfoxides; Treatment Outcome | 2005 |
Intravenous proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Biological Availability; Drug Interactions; Esomeprazole; Humans; Hydrogen-Ion Concentration; Injections, Intravenous; Lansoprazole; Pantoprazole; Proton Pump Inhibitors; Stomach; Sulfoxides | 2006 |
Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adverse Drug Reaction Reporting Systems; Enzyme Inhibitors; Esomeprazole; Humans; Lansoprazole; Muscular Diseases; Myositis; Omeprazole; Pantoprazole; Polymyositis; Proton Pump Inhibitors; Rabeprazole; Rhabdomyolysis | 2006 |
Anaphylactic reaction to drugs commonly used for gastrointestinal system diseases: 3 case reports and review of the literature.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anaphylaxis; Anti-Ulcer Agents; Benzimidazoles; Famotidine; Female; Gastroesophageal Reflux; Gastrointestinal Diseases; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Ranitidine; Skin Tests | 2006 |
Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Clinical Trials as Topic; Enzyme Inhibitors; Esomeprazole; Esophagitis, Peptic; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2006 |
[Dosaging of proton pumps inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Enzyme Inhibitors; Gastroesophageal Reflux; Genotype; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Pantoprazole; Pharmacogenetics; Polymorphism, Genetic; Proton Pump Inhibitors; Sulfoxides | 2006 |
[Safety of proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Adult; Age Factors; Aged; Animals; Anti-Ulcer Agents; Cimetidine; Enzyme Inhibitors; Famotidine; Female; Fetus; Histamine H2 Antagonists; Humans; Lactation; Lansoprazole; Meta-Analysis as Topic; Nizatidine; Omeprazole; Pantoprazole; Pregnancy; Proton Pump Inhibitors; Proton-Translocating ATPases; Rabeprazole; Ranitidine; Safety; Time Factors | 2006 |
[Clinical pharmacological aspects of the proton pump inhibitor therapy: importance of pharmacogenetic differences in the clinical practice].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Interactions; Enzyme Inhibitors; Esomeprazole; Humans; Lansoprazole; Liver; Omeprazole; Pantoprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole | 2007 |
Stereoselective disposition of proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Esomeprazole; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Stereoisomerism | 2008 |
[Proton pump inhibitors, a family of drugs in continuous expansion].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Barrett Esophagus; Duodenal Ulcer; Dyspepsia; Gastric Acid; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Rats; Stomach Ulcer | 2000 |
[Prevention of GI bleeding due to antiplatelet agents: a labyrinth!].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Humans; Lansoprazole; Omeprazole; Pantoprazole; Platelet Aggregation; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Ticlopidine | 2009 |
Impact of oesophagitis classification in evaluating healing of erosive oesophagitis after therapy with proton pump inhibitors: a pooled analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Databases, Factual; Endoscopy, Gastrointestinal; Esomeprazole; Esophagitis; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Randomized Controlled Trials as Topic; Registries; Wound Healing | 2010 |
Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Age Factors; Child; Child, Preschool; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastroesophageal Reflux; Humans; Incidence; Infant; Lansoprazole; Male; Netherlands; Omeprazole; Pantoprazole; Prognosis; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Risk Assessment; Treatment Outcome | 2011 |
The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dexlansoprazole; Esomeprazole; Humans; Lansoprazole; Magnesium; Odds Ratio; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Risk Factors; Treatment Outcome | 2014 |
Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Comparative Effectiveness Research; Dexlansoprazole; Esomeprazole; Esophagitis, Peptic; Female; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Network Meta-Analysis; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome; United States; United States Food and Drug Administration | 2017 |
High-dose vs. Low-dose Proton Pump Inhibitors post-endoscopic hemostasis in patients with bleeding peptic ulcer. A meta-analysis and meta-regression analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Dose-Response Relationship, Drug; Female; Hemostasis, Endoscopic; Humans; Lansoprazole; Male; Middle Aged; Pantoprazole; Peptic Ulcer Hemorrhage; Postoperative Hemorrhage; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Regression Analysis; Treatment Outcome | 2018 |
Proton Pump Inhibitors and Bone Health: An Update Narrative Review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Antacids; Bone Density; Dexlansoprazole; Esomeprazole; Humans; Lansoprazole; Omeprazole; Osteoporotic Fractures; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; United States | 2022 |
42 trial(s) available for pantoprazole and lansoprazole
| Article | Year |
|---|---|
Twenty-four-hour monitoring of intragastric acidity: comparison between lansoprazole 30mg and pantoprazole 40mg.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Cross-Over Studies; Female; Gastric Acid; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Monitoring, Physiologic; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides | 1997 |
Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Area Under Curve; Benzimidazoles; Breath Tests; Caffeine; Humans; Lansoprazole; Male; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides | 1998 |
A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Deglutition Disorders; Double-Blind Method; Endoscopy; Esophageal Stenosis; Gastroesophageal Reflux; Heartburn; Humans; Lansoprazole; Middle Aged; Omeprazole; Pantoprazole; Prospective Studies; Proton Pump Inhibitors; Secondary Prevention; Sulfoxides; Treatment Outcome | 1998 |
Three-day antibiotic therapy with azithromycin and tinidazole plus lansoprazole or pantoprazole to cure Helicobacter pylori infection: a pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Benzimidazoles; Drug Therapy, Combination; Duodenal Ulcer; Enzyme Inhibitors; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Pilot Projects; Prospective Studies; Proton Pump Inhibitors; Stomach Ulcer; Sulfoxides; Tinidazole | 1999 |
Lack of drug interaction between omeprazole, lansoprazole, pantoprazole and theophylline.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Area Under Curve; Benzimidazoles; Bronchodilator Agents; Cross-Over Studies; Cytochrome P-450 CYP1A2; Double-Blind Method; Drug Interactions; Female; Humans; Lansoprazole; Male; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides; Theophylline | 1999 |
Lack of a pharmacokinetic interaction between lansoprazole or pantoprazole and theophylline.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Ulcer Agents; Area Under Curve; Benzimidazoles; Biological Availability; Bronchodilator Agents; Delayed-Action Preparations; Drug Interactions; Humans; Lansoprazole; Linear Models; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Single-Blind Method; Sulfoxides; Theophylline | 2000 |
Influence of Helicobacter pylori eradication therapy on 13C aminopyrine breath test: comparison among omeprazole-, lansoprazole-, or pantoprazole-containing regimens.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aminopyrine; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Carbon Radioisotopes; Clarithromycin; Cytochrome P-450 Enzyme Inhibitors; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Sulfoxides | 2000 |
Pantoprazole versus lansoprazole in French patients with reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Method; Esophagitis, Peptic; Esophagoscopy; Female; France; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pain; Pantoprazole; Prospective Studies; Sulfoxides | 2001 |
Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Ulcer Agents; Benzimidazoles; Cross-Over Studies; Enzyme Inhibitors; Female; Humans; Hydrogen-Ion Concentration; Injections, Intravenous; Intubation, Gastrointestinal; Kinetics; Lansoprazole; Male; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Random Allocation; Rosales; Stomach; Sulfoxides | 2001 |
A comparison of simplified lansoprazole suspension administered nasogastrically and pantoprazole administered intravenously: effects on 24-h intragastric pH.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Cross-Over Studies; Enzyme Inhibitors; Female; Gastric Acid; Gastric Acidity Determination; Humans; Hydrogen-Ion Concentration; Infusions, Intravenous; Intubation, Gastrointestinal; Lansoprazole; Middle Aged; Omeprazole; Pantoprazole; Sulfoxides; Suspensions | 2001 |
Acid suppression in healthy subjects following lansoprazole or pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Ulcer Agents; Benzimidazoles; Cross-Over Studies; Gastric Acid; Gastric Acidity Determination; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Monitoring, Physiologic; Omeprazole; Pantoprazole; Single-Blind Method; Sulfoxides | 2002 |
Different effects of short-term omeprazole, lansoprazole or pantoprazole on the accuracy of the (13)C-urea breath test.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Carbon Isotopes; Drug Interactions; False Negative Reactions; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Sensitivity and Specificity; Sulfoxides; Time Factors; Urea | 2002 |
Effect of pantoprazole versus other proton pump inhibitors on 24-hour intragastric pH and basal acid output in Zollinger-Ellison syndrome.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Female; Gastric Acid; Gastric Acidity Determination; Gastrins; Humans; Lansoprazole; Male; Omeprazole; Pantoprazole; Prospective Studies; Proton Pump Inhibitors; Sulfoxides; Time Factors; Zollinger-Ellison Syndrome | 2002 |
A double-blind, randomized comparison of omeprazole Multiple Unit Pellet System (MUPS) 20 mg, lansoprazole 30 mg and pantoprazole 40 mg in symptomatic reflux oesophagitis followed by 3 months of omeprazole MUPS maintenance treatment: a Dutch multicentre t
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Method; Enzyme Inhibitors; Esophagitis, Peptic; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Patient Satisfaction; Proton Pump Inhibitors; Sulfoxides | 2002 |
Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationship, Drug; Esophagitis, Peptic; Gastric Acid; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Manometry; Middle Aged; Omeprazole; Pantoprazole; Sulfoxides | 2003 |
Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Antacids; Benzimidazoles; Cross-Over Studies; Double-Blind Method; Female; Gastric Acid; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides; Time Factors | 2003 |
Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Ulcer Agents; Benzimidazoles; Chi-Square Distribution; Cross-Over Studies; Esomeprazole; Female; Gastric Acid; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Least-Squares Analysis; Male; Middle Aged; Omeprazole; Pantoprazole; Rabeprazole; Sulfoxides; Treatment Outcome | 2003 |
Masking of 13C urea breath test by proton pump inhibitors is dependent on type of medication: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Esomeprazole; False Negative Reactions; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Prospective Studies; Proton Pump Inhibitors; Sulfoxides; Urea | 2004 |
In treatment of active duodenal ulcer and Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides; Treatment Outcome | 2003 |
Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Benzimidazoles; Cross-Over Studies; Esomeprazole; Female; Gastric Acid; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Rabeprazole; Sulfoxides; Treatment Outcome | 2004 |
Helicobacter pylori infection and the prevention of peptic ulcer with proton pump inhibitors in elderly subjects taking low-dose aspirin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Benzimidazoles; Dose-Response Relationship, Drug; Endoscopes, Gastrointestinal; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Pantoprazole; Peptic Ulcer; Prospective Studies; Proton Pump Inhibitors; Sulfoxides | 2004 |
The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abnormalities, Drug-Induced; Adult; Anti-Ulcer Agents; Benzimidazoles; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Peptic Ulcer; Pregnancy; Pregnancy Complications; Pregnancy Trimester, First; Prospective Studies; Proton Pump Inhibitors; Sulfoxides | 2005 |
Influence of various proton pump inhibitors on intestinal metaplasia in noneradicated Helicobacter pylori patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; Chronic Disease; Enzyme Inhibitors; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Intestines; Lansoprazole; Male; Metaplasia; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides | 2005 |
Recent success of pantoprazole -or lansoprazole- based clarithromycin plus amoxicillin treatment in the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Single-Blind Method; Sulfoxides; Treatment Outcome | 2004 |
Lansoprazole regimens that sustain intragastric pH > 6.0: an evaluation of intermittent oral and continuous intravenous infusion dosages.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cross-Over Studies; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Female; Gastric Acidity Determination; Genotype; Humans; Hydrogen-Ion Concentration; Infusions, Intravenous; Lansoprazole; Male; Metabolic Clearance Rate; Middle Aged; Mixed Function Oxygenases; Omeprazole; Pantoprazole; Sulfoxides; Tablets | 2006 |
Intragastric acid control in non-steroidal anti-inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Benzimidazoles; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Gastric Acid; Gastric Acidity Determination; Humans; Hydrogen-Ion Concentration; Lansoprazole; Least-Squares Analysis; Male; Middle Aged; Pantoprazole; Proton Pump Inhibitors; Sulfoxides | 2006 |
Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Ulcer Agents; Endoscopy, Gastrointestinal; Esophagitis; Female; Humans; Lansoprazole; Male; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2007 |
Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cytochrome P-450 CYP2C19; Female; Gastric Acidity Determination; Humans; Lansoprazole; Male; Mixed Function Oxygenases; Mutation; Omeprazole; Pantoprazole; Proton Pump Inhibitors | 2008 |
Ninety-six-hour wireless oesophageal pH monitoring following proton pump inhibitor administration in NERD patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Esophageal pH Monitoring; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Treatment Outcome | 2008 |
Control of 24-hour intragastric acidity with morning dosing of immediate-release and delayed-release proton pump inhibitors in patients with GERD.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Cross-Over Studies; Delayed-Action Preparations; Drug Administration Schedule; Female; Gastric Acid; Gastric Acidity Determination; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Treatment Outcome; Young Adult | 2009 |
Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Esomeprazole; Female; Gastroesophageal Reflux; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Patient Selection | 2009 |
Clinical trial: gastric acid suppression in Hispanic adults with symptomatic gastro-oesophageal reflux disease - comparator study of esomeprazole, lansoprazole and pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Cross-Over Studies; Drug Therapy, Combination; Esomeprazole; Female; Gastric Acid; Gastroesophageal Reflux; Hispanic or Latino; Humans; Lansoprazole; Male; Middle Aged; Pantoprazole; Patient Compliance; Treatment Outcome; United States; Young Adult | 2010 |
Improved HPLC method for determination of four PPIs, omeprazole, pantoprazole, lansoprazole and rabeprazole in human plasma.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Chromatography, High Pressure Liquid; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Reproducibility of Results; Young Adult | 2010 |
Inhibitory effects of intravenous lansoprazole 30 mg and pantoprazole 40 mg twice daily on intragastric acidity in healthy Chinese volunteers: a randomized, open-labeled, two-way crossover study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Base Sequence; China; Cross-Over Studies; DNA Primers; Female; Gastric Acid; Humans; Hydrogen-Ion Concentration; Infusions, Intravenous; Lansoprazole; Male; Pantoprazole; Polymerase Chain Reaction; Reference Values | 2012 |
Enantioselective disposition of omeprazole, pantoprazole, and lansoprazole in a same Brazilian subjects group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Brazil; Humans; Lansoprazole; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Stereoisomerism; Substrate Specificity; Young Adult | 2012 |
Probiotics for standard triple Helicobacter pylori eradication: a randomized, double-blind, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Bifidobacterium; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lacticaseibacillus rhamnosus; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Pantoprazole; Placebos; Probiotics; Prospective Studies; Proton Pump Inhibitors; Surveys and Questionnaires; Treatment Outcome | 2015 |
In vitro and in vivo evaluation of drug-drug interaction between dabigatran and proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Cell Line, Tumor; Cyclosporine; Dabigatran; Drug Interactions; Humans; Lansoprazole; Male; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Thrombin; Young Adult | 2015 |
Cognitive impact after short-term exposure to different proton pump inhibitors: assessment using CANTAB software.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Cognition; Esomeprazole; Female; Humans; Lansoprazole; Male; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Software; Young Adult | 2015 |
One year treatment of Barrett's oesophagus with proton pump inhibitors (a multi-center study).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Barrett Esophagus; Epithelial Cells; Esophagoscopy; Esophagus; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors | 2015 |
[Comparison on Oral versus Intravenous Proton Pump Inhibitors for Prevention of Bleeding after Endoscopic Submucosal Dissection of Gastric Lesions].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Aged; Anticoagulants; Endoscopic Mucosal Resection; Female; Gastroscopy; Humans; Injections, Intravenous; Lansoprazole; Male; Middle Aged; Odds Ratio; Pantoprazole; Postoperative Hemorrhage; Prospective Studies; Proton Pump Inhibitors; Risk Factors; Stomach Neoplasms | 2016 |
Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Cross-Over Studies; Cytochrome P-450 CYP2C19; Double-Blind Method; Esomeprazole; Female; Gastric Acid; Gastroesophageal Reflux; Genotype; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2016 |
Lansoprazole use and tuberculosis incidence in the United Kingdom Clinical Practice Research Datalink: A population based cohort.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Cohort Studies; Female; Humans; Incidence; Lansoprazole; Male; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Tuberculosis; United Kingdom | 2017 |
115 other study(ies) available for pantoprazole and lansoprazole
| Article | Year |
|---|---|
(H+,K+)-ATPase inhibiting 2-[(2-pyridylmethyl)sulfinyl]benzimidazoles. 4. A novel series of dimethoxypyridyl-substituted inhibitors with enhanced selectivity. The selection of pantoprazole as a clinical candidate.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Adenosine Triphosphate; Animals; Benzimidazoles; Dogs; Gastric Mucosa; H(+)-K(+)-Exchanging ATPase; Omeprazole; Pantoprazole; Pyridines; Rabbits; Structure-Activity Relationship; Sulfoxides | 1992 |
Nicotinamide derivatives as a new class of gastric H+/K(+)-ATPase inhibitors. 1. Synthesis and structure-activity relationships of N-substituted 2-(benzhydryl- and benzylsulfinyl)nicotinamides.
Topics: Aminopyrine; Animals; Bucladesine; Enzyme Inhibitors; Gastric Acid; Hydrogen-Ion Concentration; Kinetics; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Molecular Structure; Niacinamide; Parietal Cells, Gastric; Proton Pump Inhibitors; Pyridines; Rabbits; Rats; Rats, Wistar; Structure-Activity Relationship | 1997 |
Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzimidazoles; Biological Transport; Caco-2 Cells; Digoxin; Drug Interactions; Enzyme Inhibitors; Epithelial Cells; Humans; Lansoprazole; LLC-PK1 Cells; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Proton Pumps; Sulfoxides; Swine | 2001 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Antiprotozoal activity of proton-pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antiprotozoal Agents; Drug Design; Entamoeba histolytica; Giardia lamblia; Humans; Lansoprazole; Omeprazole; Pantoprazole; Parasitic Diseases; Proton Pump Inhibitors; Rabeprazole; Trichomonas vaginalis | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
Topics: Animals; Dose-Response Relationship, Drug; Enzyme Inhibitors; HEK293 Cells; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Mice; Models, Molecular; Molecular Structure; Structure-Activity Relationship; Substrate Specificity | 2012 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
Repositioning proton pump inhibitors as anticancer drugs by targeting the thioesterase domain of human fatty acid synthase.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Drug Repositioning; Fatty Acid Synthases; Humans; Hydrogen-Ion Concentration; Lansoprazole; Palmitic Acid; Palmitoyl-CoA Hydrolase; Protein Structure, Tertiary; Proton Pump Inhibitors | 2015 |
Identification of ebselen as a potent inhibitor of insulin degrading enzyme by a drug repurposing screening.
Topics: Azoles; Biocatalysis; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Repositioning; Enzyme Inhibitors; High-Throughput Screening Assays; Humans; Insulysin; Isoindoles; Molecular Structure; Organoselenium Compounds; Structure-Activity Relationship | 2019 |
The H+, K(+)-ATPase inhibitor pantoprazole (BY1023/SK&F96022) interacts less with cytochrome P450 than omeprazole and lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; 7-Alkoxycoumarin O-Dealkylase; Adenosine Triphosphatases; Animals; Benzimidazoles; Biotransformation; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Ethylmorphine-N-Demethylase; Female; H(+)-K(+)-Exchanging ATPase; Kinetics; Lansoprazole; Liver; Omeprazole; Pantoprazole; Pyrazoles; Rats; Rats, Inbred Strains; Sulfoxides | 1991 |
Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Pantoprazole; Peptic Ulcer; Polymorphism, Genetic; Proton Pump Inhibitors; Structure-Activity Relationship; Sulfoxides | 1996 |
[Do other proton pump blockers have advantages over Antra (omeprazole)?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Humans; Lansoprazole; Omeprazole; Pantoprazole; Peptic Ulcer; Structure-Activity Relationship; Sulfoxides | 1996 |
[2 new proton pump inhibitors. Possibilities of pantoprazole and lansoprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Humans; Lansoprazole; Omeprazole; Pantoprazole; Peptic Ulcer; Structure-Activity Relationship; Sulfoxides; Treatment Outcome | 1996 |
Effects of benzimidazole derivatives on cytochrome P450 1A1 expression in a human hepatoma cell line.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; beta-Naphthoflavone; Cell Line; Cytochrome P-450 CYP1A1; Enzyme Activation; Humans; Lansoprazole; Omeprazole; Pantoprazole; Rabeprazole; RNA, Messenger; Sulfoxides | 1997 |
Chiral resolution of pantoprazole sodium and related sulfoxides by complex formation with bovine serum albumin in capillary electrophoresis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Electrophoresis, Capillary; Hydrogen-Ion Concentration; Lansoprazole; Omeprazole; Pantoprazole; Serum Albumin, Bovine; Spectrophotometry, Ultraviolet; Stereoisomerism; Sulfoxides | 1997 |
Effects of pantoprazole on xenobiotic metabolizing enzymes in rat liver microsomes: a comparison with other proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Benzimidazoles; Blotting, Western; Cytochrome P-450 Enzyme System; Cytochromes b5; Enzyme Induction; Enzyme Inhibitors; Female; Lansoprazole; Microsomes, Liver; NADPH-Ferrihemoprotein Reductase; Omeprazole; Organ Size; Pantoprazole; Proton Pump Inhibitors; Rats; Rats, Sprague-Dawley; Sulfoxides | 1997 |
Proton-pump inhibitors: three of a kind?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Enzyme Inhibitors; Humans; Lansoprazole; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Sulfoxides | 1997 |
Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amino Acid Sequence; Animals; Anti-Ulcer Agents; Benzimidazoles; Enzyme Inhibitors; Gastric Acid; H(+)-K(+)-Exchanging ATPase; Indicators and Reagents; Lansoprazole; Molecular Sequence Data; Omeprazole; Oxidoreductases; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sequence Homology, Amino Acid; Sphingosine; Stomach; Sulfhydryl Compounds; Sulfoxides; Swine | 1997 |
An evaluation of the CYP1A induction potential of pantoprazole in primary rat hepatocytes: a comparison with other proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Benzimidazoles; Blotting, Western; Cells, Cultured; Cytochrome P-450 CYP1A1; Enzyme Induction; Enzyme Inhibitors; Female; Lansoprazole; Liver; Microsomes, Liver; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rats; Rats, Sprague-Dawley; Sulfoxides | 1997 |
Selective inhibition of the gastric H+,K(+)-ATPase by omeprazole and related compounds.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Benzimidazoles; Binding Sites; Enzyme Inhibitors; Gastric Mucosa; H(+)-K(+)-Exchanging ATPase; Humans; Kinetics; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Structure-Activity Relationship; Sulfoxides; Valinomycin | 1997 |
Effects of proton pump inhibitors on thyroid hormone metabolism in rats: a comparison of UDP-glucuronyltransferase induction.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Benzimidazoles; Bile; Enzyme Inhibitors; Female; Glucuronosyltransferase; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rats; Rats, Sprague-Dawley; Sulfoxides; Thyroid Hormones | 1997 |
Growth inhibitory and bactericidal activities of lansoprazole compared with those of omeprazole and pantoprazole against Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Growth Inhibitors; Helicobacter pylori; Humans; Lansoprazole; Microscopy, Electron, Scanning; Omeprazole; Pantoprazole; Sulfoxides; Urease | 1998 |
An evaluation of the cytochrome P450 induction potential of pantoprazole in primary human hepatocytes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Benzimidazoles; Blotting, Western; Cells, Cultured; Cytochrome P-450 CYP1A1; Cytochrome P-450 Enzyme System; Enzyme Induction; Female; Humans; Lansoprazole; Liver; Male; Methylcholanthrene; Middle Aged; Omeprazole; Pantoprazole; Rifampin; Steroid Hydroxylases; Structure-Activity Relationship; Sulfoxides | 1998 |
[Drug interactions. Proton pump inhibitors. 1].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides | 1998 |
[Drug interactions. Proton pump inhibitors II].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Lansoprazole; Liver; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides | 1998 |
Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetic Acid; Animals; Anti-Ulcer Agents; Benzimidazoles; Bicarbonates; Dose-Response Relationship, Drug; Duodenal Ulcer; Enzyme Inhibitors; Epirizole; Gastric Acid; Lansoprazole; Male; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rats; Rats, Sprague-Dawley; Sulfoxides; Wound Healing | 1999 |
Effect of various salts on the stability of lansoprazole, omeprazole, and pantoprazole as determined by high-performance liquid chromatography.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Chromatography, High Pressure Liquid; Drug Stability; Enzyme Inhibitors; Hydrogen-Ion Concentration; Lansoprazole; Omeprazole; Pantoprazole; Reproducibility of Results; Salts; Sulfoxides; Time Factors | 1999 |
Lichenoid drug eruption with proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Benzimidazoles; Drug Eruptions; Enzyme Inhibitors; Humans; Lansoprazole; Lichenoid Eruptions; Male; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides | 2000 |
Spectrophotometric methods for the determination of lansoprazole and pantoprazole sodium sesquihydrate.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Calibration; Capsules; Hydrogen-Ion Concentration; Indicators and Reagents; Lansoprazole; Omeprazole; Pantoprazole; Pharmaceutical Solutions; Spectrophotometry, Ultraviolet; Sulfoxides; Tablets | 2000 |
Treatment of Helicobacter pylori infection: is less more?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Clinical Trials as Topic; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Pantoprazole; Penicillins; Proton Pump Inhibitors; Sulfoxides; Time Factors | 2000 |
The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adult; Adverse Drug Reaction Reporting Systems; Age Distribution; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimidazoles; Cohort Studies; Diarrhea; Drug Prescriptions; England; Family Practice; Female; Headache; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides | 2000 |
Haloperidol-stomach lesions attenuation by pentadecapeptide BPC 157, omeprazole, bromocriptine, but not atropine, lansoprazole, pantoprazole, ranitidine, cimetidine and misoprostol in mice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Atropine; Benzimidazoles; Bromocriptine; Cimetidine; Disease Models, Animal; Domperidone; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Haloperidol; Indomethacin; Lansoprazole; Male; Mice; Mice, Inbred Strains; Misoprostol; Omeprazole; Pantoprazole; Peptide Fragments; Proteins; Ranitidine; Stomach Diseases; Sulfoxides | 2001 |
Reversible pheripheral edema in female patients taking proton pump inhibitors for peptic acid diseases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Edema; Female; Humans; Lansoprazole; Middle Aged; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Sulfoxides | 2001 |
Proton pump inhibitors: a study of GPs' prescribing.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Costs; Drug Prescriptions; Drug Utilization; England; Family Practice; Female; Health Services Research; Hospitals, Teaching; Humans; Lansoprazole; Male; Omeprazole; Pantoprazole; Practice Patterns, Physicians'; Proton Pump Inhibitors; Sulfoxides | 2001 |
Relative efficacies of gastric proton-pump inhibitors on a milligram basis: desired and undesired SH reactions. Impact of chirality.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Enzyme Inhibitors; Esomeprazole; Half-Life; Humans; Hydrogen-Ion Concentration; Lansoprazole; Omeprazole; Pantoprazole; Parietal Cells, Gastric; Prodrugs; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2001 |
Conformational analysis: a new approach by means of chemometrics.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Lansoprazole; Models, Molecular; Molecular Conformation; Omeprazole; Pantoprazole; Pharmaceutical Preparations; Sulfoxides; Thermodynamics | 2002 |
Proton pump inhibitors: an update.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Drug Interactions; Esomeprazole; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2002 |
[Submicroscopic aspects of the mechanism of inhibitors of H+/K+-ATPase in gastric parietal cells].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Enzyme Inhibitors; Histamine H2 Antagonists; Humans; Hydrogen-Ion Concentration; Lansoprazole; Omeprazole; Pantoprazole; Parietal Cells, Gastric; Proton Pump Inhibitors; Sulfoxides | 2002 |
Spectrophotometric determination of omeprazole, lansoprazole and pantoprazole in pharmaceutical formulations.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Chemistry, Pharmaceutical; Lansoprazole; Omeprazole; Pantoprazole; Spectrophotometry, Ultraviolet; Sulfoxides | 2002 |
[In small steps to far ahead. Diminished risk of interactions as definite advantage].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Interactions; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides | 2002 |
Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CYP3A7 and CYP3A43.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cell Line, Tumor; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Gene Expression Regulation; Humans; Hypericum; Lansoprazole; Omeprazole; Pantoprazole; Plant Preparations; Rabeprazole; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfoxides | 2003 |
A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adverse Drug Reaction Reporting Systems; Anti-Ulcer Agents; Anticoagulants; Benzimidazoles; Drug Interactions; Gastrointestinal Diseases; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides; United States; United States Food and Drug Administration | 2003 |
["Mirror, mirror on the wall which is the best proton pump inhibitor of all?"].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Antifibrinolytic Agents; Benzimidazoles; Drug Interactions; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides; Vitamin K | 2003 |
The acidity index: a simple approach to the measurement of gastric acidity.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Female; Gastric Acid; Gastric Acidity Determination; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides | 2004 |
Pantoprazole treatment does not invoke anti-inflammatory properties in vivo.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents; Anti-Ulcer Agents; Benzimidazoles; Carrageenan; Helicobacter pylori; Inflammation; Lansoprazole; Male; Neutrophils; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rats; Rats, Wistar; Sulfoxides | 2004 |
Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Esomeprazole; Humans; Lansoprazole; Liver; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Proton Pumps; Rabeprazole; Sulfoxides | 2004 |
Determination of pantoprazole in human plasma by LC-MS-MS using lansoprazole as internal standard.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Calibration; Chemistry, Pharmaceutical; Chromatography, Liquid; Humans; Indicators and Reagents; Lansoprazole; Mass Spectrometry; Omeprazole; Pantoprazole; Quality Control; Reference Standards; Reproducibility of Results; Sulfoxides; Therapeutic Equivalency | 2004 |
Chiral separation of omeprazole and several related benzimidazoles using supercritical fluid chromatography.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alcohols; Amylose; Benzimidazoles; Chromatography; Lansoprazole; Models, Chemical; Omeprazole; Pantoprazole; Pressure; Rabeprazole; Stereoisomerism; Sulfoxides; Temperature; Time Factors | 2004 |
Pachydermia is not diagnostic of active laryngopharyngeal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimidazoles; Drug Therapy, Combination; Female; Gastric Acidity Determination; Gastroesophageal Reflux; Humans; Hypertrophy; Lansoprazole; Laryngeal Diseases; Laryngeal Mucosa; Laryngoscopy; Long-Term Care; Male; Middle Aged; Omeprazole; Pantoprazole; Pharyngeal Diseases; Proton Pump Inhibitors; Retrospective Studies; Sulfoxides; Treatment Outcome; Voice Disorders | 2004 |
[Choice of proton pump inhibitors--does it play any role?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationship, Drug; Drugs, Generic; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2004 |
Results of triple eradication therapy in Japanese children: a retrospective multicenter study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Child; Child, Preschool; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Humans; Infant; Lansoprazole; Metronidazole; Microbial Sensitivity Tests; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Sulfoxides | 2004 |
Cost effective prescribing of proton pump inhibitors (PPI's) in the GMS Scheme.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Community Pharmacy Services; Cost-Benefit Analysis; Drug Costs; Enzyme Inhibitors; Health Care Surveys; Humans; Ireland; Lansoprazole; National Health Programs; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2005 |
Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esomeprazole; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides; United Kingdom | 2005 |
Hydroxyl radical scavenging reactivity of proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Benzimidazoles; Cattle; Copper Sulfate; Deoxyribose; Enzyme Inhibitors; Erythrocytes; Free Radical Scavengers; Heme; Hyaluronic Acid; Hydroxyl Radical; Iron Compounds; Lansoprazole; Omeprazole; Pantoprazole; Proton Pumps; Sulfides; Sulfoxides | 2006 |
A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequences.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimidazoles; British Columbia; Cost Savings; Databases, Factual; Drug Utilization Review; Female; Health Services for the Aged; Hospitalization; Humans; Insurance, Pharmaceutical Services; Lansoprazole; Male; Omeprazole; Pantoprazole; Practice Patterns, Physicians'; Rabeprazole; Sulfoxides | 2006 |
Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Drug Administration Schedule; Enzyme Inhibitors; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides; Time Factors | 2006 |
Reversed-phase high performance liquid chromatographic method for the determination of lansoprazole, omeprazole and pantoprazole sodium sesquihydrate in presence of their Acid-induced degradation products.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acids; Anti-Ulcer Agents; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Drug Stability; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors | 2006 |
Effect of proton pump inhibitors on hepatic regeneration.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Benzimidazoles; Enzyme Inhibitors; Female; Hepatectomy; Ki-67 Antigen; Lansoprazole; Liver; Liver Regeneration; Male; Omeprazole; Organ Size; Pantoprazole; Proton Pump Inhibitors; Rats; Rats, Wistar; Sulfoxides | 2006 |
An in vitro investigation on acid catalyzed reactions of proton pump inhibitors in the absence of an electrophile.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acids; Anti-Ulcer Agents; Catalysis; Dimerization; Drug Stability; Electrochemistry; Enzyme Inhibitors; Hydrogen-Ion Concentration; Lansoprazole; Omeprazole; Pantoprazole; Polarography; Proton Pump Inhibitors | 2006 |
Preparative chiral chromatography and chiroptical characterization of enantiomers of omeprazole and related benzimidazoles.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Chromatography; Chromatography, Supercritical Fluid; Circular Dichroism; Enzyme Inhibitors; Lansoprazole; Models, Chemical; Molecular Conformation; Molecular Structure; Omeprazole; Pantoprazole; Rabeprazole; Stereoisomerism | 2007 |
Pattern of proton pump inhibitor calls to Texas poison centers, 1998-2004.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Animals; Child; Child, Preschool; Enzyme Inhibitors; Female; Humans; Lansoprazole; Male; Omeprazole; Pantoprazole; Poison Control Centers; Poisoning; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Texas | 2007 |
Long-term proton pump inhibitor use in children: a retrospective review of safety.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Child; Child, Preschool; Esophagitis; Female; Gastrins; Humans; Lansoprazole; Liver Function Tests; Male; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Vitamin B 12 | 2008 |
Subacute cutaneous lupus erythematosus induced or exacerbated by proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Autoantibodies; Duodenal Ulcer; Esophagitis; Female; Humans; Lansoprazole; Lupus Erythematosus, Cutaneous; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Skin | 2008 |
[Drug treatment and surgical indications in gastroesophageal reflux].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clinical Trials as Topic; Fundoplication; Gastroesophageal Reflux; Histamine Antagonists; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Time Factors | 2007 |
Semipreparative chiral supercritical fluid chromatography in the fractionation of lansoprazole and two related antiulcer drugs enantiomers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Chemical Fractionation; Chemistry Techniques, Analytical; Chemistry, Pharmaceutical; Chromatography; Chromatography, Supercritical Fluid; Equipment Design; Lansoprazole; Models, Chemical; Pantoprazole; Pharmaceutical Preparations; Rabeprazole; Stereoisomerism; Time Factors | 2008 |
[General practitioners' management of gastroesophageal reflux in France in 2005: a pharmacoeconomic study].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Costs and Cost Analysis; Esomeprazole; Family Practice; Female; France; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pumps; Rabeprazole | 2008 |
Omeprazole, lansoprazole and pantoprazole had no effect on blood pressure and electrocardiogram of anesthetized rat.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anesthesia; Animals; Blood Pressure; Dose-Response Relationship, Drug; Electric Stimulation; Electrocardiography; Female; Heart Atria; Heart Rate; Humans; In Vitro Techniques; Injections, Intravenous; Lansoprazole; Male; Myocardial Contraction; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rats; Rats, Wistar | 2008 |
[Comparison of Helicobacter pylori eradication rate in patients with non-ulcer dyspepsia and peptic ulcer diseases according to proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Data Interpretation, Statistical; Drug Therapy, Combination; Dyspepsia; Enzyme Inhibitors; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole | 2008 |
Simultaneous estimation of four proton pump inhibitors--lansoprazole, omeprazole, pantoprazole and rabeprazole: development of a novel generic HPLC-UV method and its application to clinical pharmacokinetic study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chromatography, High Pressure Liquid; Drug Stability; Humans; Isoxazoles; Lansoprazole; Male; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Zonisamide | 2009 |
[13C]-pantoprazole breath test to predict CYP2C19 phenotype and efficacy of a proton pump inhibitor, lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Breath Tests; Cytochrome P-450 CYP2C19; Enzyme Inhibitors; Female; Humans; Lansoprazole; Male; Middle Aged; Pantoprazole; Proton Pump Inhibitors; Young Adult | 2009 |
Novel approaches to inhibition of gastric acid secretion.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Enzyme Inhibitors; Gastric Acid; Gastroesophageal Reflux; Histamine Antagonists; Histamine H2 Antagonists; Humans; Hydrogen-Ion Concentration; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Ranitidine | 2010 |
Direct injection of native aqueous matrices by achiral-chiral chromatography ion trap mass spectrometry for simultaneous quantification of pantoprazole and lansoprazole enantiomers fractions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Humic Substances; Lansoprazole; Least-Squares Analysis; Pantoprazole; Reproducibility of Results; Rivers; Sensitivity and Specificity; Serum Albumin, Bovine; Stereoisomerism; Tandem Mass Spectrometry; Water Pollutants, Chemical | 2011 |
The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Drug Interactions; Enzyme Inhibitors; Esomeprazole; Hepatocytes; Humans; Inhibitory Concentration 50; Lansoprazole; Microsomes; Microsomes, Liver; Omeprazole; Pantoprazole; Protein Binding; Proton Pump Inhibitors; Recombinant Proteins; Ticlopidine | 2011 |
Proton pump inhibitors omeprazole, lansoprazole and pantoprazole induce relaxation in the rat lower oesophageal sphincter.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Angiotensins; Animals; Carbachol; Electric Stimulation; Esophageal Sphincter, Lower; Gastroesophageal Reflux; Lansoprazole; Muscle Relaxation; Muscle, Smooth; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rats; Rats, Wistar | 2011 |
In vitro evaluation of phototoxic properties of proton pump inhibitors, H2-receptor antagonists and statins.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Ascorbic Acid; Cimetidine; Erythrocytes; Famotidine; Hemolysis; Histamine H2 Antagonists; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lansoprazole; Lovastatin; Nizatidine; Omeprazole; Pantoprazole; Pravastatin; Proton Pump Inhibitors; Ranitidine; Ultraviolet Rays | 2012 |
Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Biotransformation; Cells, Cultured; Computer Simulation; Cytochrome P-450 CYP2C19; Dealkylation; Dexlansoprazole; Diazepam; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Esomeprazole; Hepatocytes; Humans; Kinetics; Lansoprazole; Liver; Microsomes, Liver; Models, Biological; NADP; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Recombinant Proteins; Substrate Specificity | 2012 |
[Factors affecting efficacy of gastroesophageal reflux disease treatment with proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Treatment Outcome | 2012 |
Cutaneous reactions to proton pump inhibitors: a case-control study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Angioedema; Case-Control Studies; Chi-Square Distribution; Drug Eruptions; Esomeprazole; Exanthema; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Prevalence; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Statistics, Nonparametric; Stevens-Johnson Syndrome; Thailand; Urticaria; Young Adult | 2012 |
Risk of adverse cardiovascular outcomes and all-cause mortality associated with concomitant use of clopidogrel and proton pump inhibitors in elderly patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Case-Control Studies; Clopidogrel; Cohort Studies; Coronary Artery Bypass; Drug Interactions; Drug Therapy, Combination; Esomeprazole; Female; Humans; Lansoprazole; Male; Myocardial Infarction; Omeprazole; Pantoprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Rabeprazole; Risk; Stroke; Ticlopidine | 2013 |
Inhibition of lysosomal enzyme activities by proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Cell Line; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzymes; Humans; Hydrogen-Ion Concentration; Immune System; Immunotherapy; Lansoprazole; Lysosomes; Male; Mass Spectrometry; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Omeprazole; Pantoprazole; Prodrugs; Proton Pump Inhibitors; Spleen | 2013 |
Normal and polar-organic-phase high-performance liquid chromatographic enantioresolution of omeprazole, rabeprazole, lansoprazole and pantoprazole using monochloro-methylated cellulose-based chiral stationary phase and determination of dexrabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Chromatography, High Pressure Liquid; Lansoprazole; Omeprazole; Pantoprazole; Rabeprazole; Stereoisomerism | 2014 |
Patterns of proton pump inhibitor utilization in gastroesophageal reflux disease and the effect of restrictions on reimbursement: a nationwide prescription database study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Drug Substitution; Esomeprazole; Gastroesophageal Reflux; Health Policy; Humans; Insurance, Health, Reimbursement; Lansoprazole; Norway; Omeprazole; Pantoprazole; Proton Pump Inhibitors | 2013 |
Reaction of proton pump inhibitors with model peptides results in novel products.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Catalytic Domain; Cysteine; Enzyme Inhibitors; H(+)-K(+)-Exchanging ATPase; Hydrogen-Ion Concentration; Lansoprazole; Mass Spectrometry; Molecular Structure; Omeprazole; Pantoprazole; Peptides; Proton Pump Inhibitors; Pyridones; Sulfamerazine | 2013 |
Slow, spontaneous degradation of lansoprazole, omeprazole and pantoprazole tablets: isolation and structural characterization of the toxic antioxidants 3H-benzimidazole-2-thiones.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Antioxidants; Benzimidazoles; Chromatography, High Pressure Liquid; Drug Stability; Indicators and Reagents; Lansoprazole; Magnetic Resonance Spectroscopy; Omeprazole; Pantoprazole; Spectrometry, Mass, Electrospray Ionization; Tablets; Temperature; Thiones | 2013 |
Relaxant effect of proton pump inhibitors on in vitro myometrium from pregnant women.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Apamin; Calcium; Dinoprostone; Esomeprazole; Female; Humans; In Vitro Techniques; Indomethacin; Lansoprazole; Muscle Contraction; Myometrium; NG-Nitroarginine Methyl Ester; Omeprazole; Oxytocin; Pantoprazole; Peptides; Potassium Chloride; Pregnancy; Proton Pump Inhibitors; Rabeprazole; Tocolytic Agents | 2014 |
The stereoselectivity of CYP2C19 on R- and S-isomers of proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Binding Sites; Cytochrome P-450 CYP2C19; Lansoprazole; Molecular Conformation; Molecular Dynamics Simulation; Omeprazole; Pantoprazole; Protein Binding; Protein Structure, Tertiary; Proton Pump Inhibitors; Stereoisomerism; Thermodynamics | 2014 |
Comparative risk of ischemic stroke among users of clopidogrel together with individual proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Brain Ischemia; Clopidogrel; Data Interpretation, Statistical; Drug Therapy, Combination; Esomeprazole; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proportional Hazards Models; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Risk; Stroke; Ticlopidine | 2015 |
In vitro study of the variable effects of proton pump inhibitors on voriconazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antifungal Agents; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Drug Interactions; Esomeprazole; Humans; Lansoprazole; Microsomes, Liver; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Voriconazole | 2015 |
Lansoprazole is an antituberculous prodrug targeting cytochrome bc1.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Antitubercular Agents; Cell Line; Drug Discovery; Drug Resistance, Bacterial; Electron Transport Complex III; Fibroblasts; High-Throughput Screening Assays; Humans; Lansoprazole; Macrophages; Mice; Mycobacterium tuberculosis; Omeprazole; Pantoprazole; Prodrugs; Proton Pump Inhibitors; Sulfides; Tuberculosis, Multidrug-Resistant | 2015 |
Negative Effect of Proton-pump Inhibitors (PPIs) on Helicobacter pylori Growth, Morphology, and Urease Test and Recovery after PPI Removal--An In vitro Study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Female; Helicobacter pylori; Humans; Lansoprazole; Male; Microbial Sensitivity Tests; Microbial Viability; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Urease; Young Adult | 2016 |
Medical and non-medical predictors of initiating long-term use of proton pump inhibitors: a nationwide cohort study of first-time users during a 10-year period.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; Esomeprazole; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Young Adult | 2016 |
Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administrative Claims, Healthcare; Adult; Aged; Case-Control Studies; Esomeprazole; Female; Hepatic Encephalopathy; Humans; Incidence; Insurance, Health; Lansoprazole; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Taiwan | 2017 |
Empirical treatment of outpatients with gastroesophageal reflux disease with proton pump inhibitors: A survey of Chinese patients (the ENLIGHT Study).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Asian People; Esomeprazole; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Outpatients; Pantoprazole; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Time Factors; Treatment Outcome; Young Adult | 2018 |
Associations of proton pump inhibitors and hospitalization due to hyponatremia: A population-based case-control study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Esomeprazole; Female; Hospitalization; Humans; Hyponatremia; Lansoprazole; Logistic Models; Male; Middle Aged; Multivariate Analysis; Omeprazole; Pantoprazole; Population; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Sweden; Young Adult | 2019 |
The status of proton pump inhibitor use: a prescription survey of 45 hospitals in China.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; China; Comorbidity; Esomeprazole; Female; Health Care Surveys; Hospitals; Humans; Inappropriate Prescribing; Lansoprazole; Male; Middle Aged; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Young Adult | 2019 |
Comparison of the gastric acid inhibition function among lansoprazole, pantoprazole, and their respective stereoisomers in healthy Chinese subjects
.
Topics: Anti-Ulcer Agents; Gastric Acidity Determination; Healthy Volunteers; Humans; Hydrogen-Ion Concentration; Lansoprazole; Pantoprazole; Stereoisomerism | 2019 |
Qualimetric analysis of proton pump inhibitors in Ukraine.
Topics: Dexlansoprazole; Esomeprazole; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Quality Control; Rabeprazole; Ukraine | 2019 |
Proton Pump Inhibitor-Treated H. pylori Adjust Cell Envelope Fatty Acid and Cholesterol Content to Survive.
Topics: Cell Membrane; Cholesterol; Fatty Acids; Helicobacter pylori; Lansoprazole; Microbial Sensitivity Tests; Microbial Viability; Pantoprazole; Proton Pump Inhibitors | 2020 |
Inhibition of monoglyceride lipase by proton pump inhibitors: investigation using docking and in vitro experiments.
Topics: Humans; Lansoprazole; Molecular Docking Simulation; Molecular Structure; Monoacylglycerol Lipases; Pantoprazole; Protein Binding; Proton Pump Inhibitors; Rabeprazole; Substrate Specificity | 2020 |
Effect of proton pump inhibitors on voriconazole concentrations in Chinese patients with malignant hematological diseases.
Topics: Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Drug Interactions; Female; Humans; Lansoprazole; Male; Molecular Docking Simulation; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Retrospective Studies; Voriconazole | 2020 |
Comparison of Antioxidant Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole.
Topics: Antioxidants; Ascorbic Acid; Biphenyl Compounds; Esomeprazole; Free Radicals; In Vitro Techniques; Inhibitory Concentration 50; Lansoprazole; Omeprazole; Pantoprazole; Picrates; Proton Pump Inhibitors; Rabeprazole; Spectrophotometry | 2020 |
Simultaneous enantioselective determination of omeprazole, rabeprazole, lansoprazole, and pantoprazole enantiomers in human plasma by chiral liquid chromatography-tandem mass spectrometry.
Topics: Chromatography, High Pressure Liquid; Humans; Lansoprazole; Molecular Structure; Omeprazole; Pantoprazole; Rabeprazole; Stereoisomerism; Tandem Mass Spectrometry | 2020 |
Pantoprazole, a proton-pump inhibitor, impairs human sperm motility and capacitation in vitro.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Fertilization; Humans; Lansoprazole; Male; Membrane Potentials; Middle Aged; Omeprazole; Pantoprazole; Phosphorylation; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Semen Analysis; Sperm Capacitation; Sperm Maturation; Sperm Motility; Spermatozoa; Young Adult | 2020 |
Spectroscopic study of in situ-formed metallocomplexes of proton pump inhibitors in water.
Topics: Coordination Complexes; Ferric Compounds; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Spectrophotometry; Transition Elements; Water | 2021 |
Simultaneous Quantitative Analysis of Six Proton-Pump Inhibitors with a Single Marker and Evaluation of Stability of Investigated Drugs in Polypropylene Syringes for Continuous Infusion Use.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chromatography, High Pressure Liquid; Drugs, Investigational; Esomeprazole; Humans; Lansoprazole; Molecular Structure; Omeprazole; Pantoprazole; Polypropylenes; Proton Pump Inhibitors; Rabeprazole | 2020 |
Pantoprazole-induced Thrombocytopenia: Unresponsive to Corticosteroid and Thrombocyte Concentrate Transfusion.
Topics: Blood Platelets; Humans; Lansoprazole; Male; Middle Aged; Pantoprazole; Proton Pump Inhibitors; Thrombocytopenia | 2023 |
Proton pump inhibitor therapy and risk of knee replacement surgery: a general population-based cohort study.
Topics: Cohort Studies; Esomeprazole; Humans; Lansoprazole; Omeprazole; Osteoarthritis, Knee; Pantoprazole; Proton Pump Inhibitors; Rabeprazole | 2022 |
Acid suppressants use and risk of atherosclerotic cardiovascular disease in middle-aged and older adults.
Topics: Aged; Antihypertensive Agents; Atherosclerosis; Cardiovascular Diseases; Histamine; Humans; Lansoprazole; Middle Aged; Omeprazole; Pantoprazole; Prospective Studies; Proton Pump Inhibitors; Risk Assessment; Risk Factors | 2022 |
Proton pump inhibitor-induced risk of chronic kidney disease is associated with increase of indoxyl sulfate synthesis via inhibition of CYP2E1 protein degradation.
Topics: Animals; Cytochrome P-450 CYP2E1; Indican; Lansoprazole; Mice; Omeprazole; Pantoprazole; Proteolysis; Proton Pump Inhibitors; Renal Insufficiency, Chronic; Uremic Toxins | 2022 |